Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chitosan platelet rich plasma - ChitogenX

Drug Profile

Chitosan platelet rich plasma - ChitogenX

Alternative Names: Chitosan PRP-ChitogenX; ORTHO-C; Ortho-C/PRP; ORTHO-M; Ortho-M/PRP; ORTHO-R; Ortho-R/PRP; ORTHO-V; Ortho-V/PRP

Latest Information Update: 27 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ortho Regenerative Technologies
  • Developer ChitogenX
  • Class Antihaemorrhagics; Antirheumatics; Biopolymers; Cell therapies; Polysaccharides
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Rotator cuff injuries
  • Preclinical Cartilage disorders; Ligament injuries; Meniscus disorders; Osteoarthritis; Spinal cord injuries

Most Recent Events

  • 27 Sep 2023 ChitogenX completes enrolment in its Phase-I/II trial for Rotator cuff injuries (Adjunctive treatment) in USA
  • 29 Sep 2022 ChitogenX receives notice of issuance for ORTHO-R soft tissue repair platform from Canada and the Europe
  • 21 Sep 2022 Preclinical trials in Osteoarthritis in USA (Intra-articular) (Chitogenx pipeline, September 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top